Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.

Nature communications - 10 May 2017

Shin Seung-Min, Choi Dong-Ki, Jung Keunok, Bae Jeomil, Kim Ji-Sun, Park Seong-Wook, Song Ki-Hoon, Kim Yong-Sung

Abstract excerpt

Oncogenic Ras mutants, frequently detected in human cancers, are high-priority anticancer drug targets. However, direct inhibition of oncogenic Ras mutants with small molecules has been extremely challenging. Here we report the development of a human IgG1 format antibody, RT11, which internalizes into the cytosol of living cells and selectively binds to the activated GTP-bound form of various oncogenic Ras...

Topics

Join the communities discussing this publication.

Cytosol
HL-60 Cells
HT29 Cells
K562 Cells
MCF-7 Cells

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Transplantation

Protein Interaction Domains and Motifs

Source

Open in PubMed Open full text

Identifiers

PMID: 28489072
DOI: 10.1038/ncomms15090
PMCID: PMC5436137

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.PMID 28489072Read ↗

Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.Semantic proximity Read ↗

Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS.Semantic proximity Read ↗

Small molecule inhibitors of RAS-effector protein interactions derived using an intracellular antibody fragment.Semantic proximity Read ↗

Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteinsSemantic proximity Read ↗

A Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth and Induces Antitumor Immunity in Gastrointestinal CancerSemantic proximity Read ↗

An engineered chimeric toxin that cleaves activated mutant and wild-type RAS inhibits tumor growth.Semantic proximity Read ↗

Inhibition of tumor growth by a novel engineered chimeric toxin that cleaves activated mutant and wild-type RASSemantic proximity Read ↗

A human monoclonal antibody 264RAD targeting αvβ6 integrin reduces tumour growth and metastasis, and modulates key biomarkers in vivoSemantic proximity Read ↗

RasIns: Genetically Encoded Intrabodies of Activated Ras Proteins.Semantic proximity Read ↗

High Affinity Promotes Internalization of Engineered Antibodies Targeting FGFR1Semantic proximity Read ↗

Intracellular antibodies and cancer: New technologies offer therapeutic opportunitiesSemantic proximity Read ↗

Intracellular expression of single chain antibodies reverts ErbB-2 transformation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.